- Advertisement -

- Advertisement -


CDC panel adjourns without vote on extending Johnson & Johnson COVID vaccine

A Centers for Disease Control and Prevention advisory committee did not vote Wednesday on whether to extend the nation’s pause on Johnson & Johnson’s COVID-19 vaccine, after experts on the panel argued there was still insufficient data to make final recommendations in light of the serious, rare blood clotting events potentially linked to the shots. 

While the CDC’s current pause on Johnson & Johnson’s vaccine is not binding, the warning issued by federal health officials on Tuesday urged that vaccinations be suspended only until the panel voted on “updated recommendations” for using the vaccine. In response to the FDA and CDC advisory on the pause, all states and D.C. and Puerto Rico have opted to temporarily stop administering this vaccine.

The CDC has yet to decide on a date to resume the panel’s discussion on the topic. 

“Your input today was incredibly helpful in terms of helping inform our work over the next week,” said Dr. Amanda Cohn, the agency’s designated federal officer for the advisory committee.

“To be very frank, I do not want to vote on this issue today,” Dr. Beth Bell, a member of the panel and a former top CDC infectious diseases official, told the committee. 

“I just don’t feel that was enough information to make an evidence-based decision. We won’t have all the information, but I think there are some things that we can gather relatively quickly, which all have to do with the benefit risk balance,” added Dr. Bell. 

Read More: CDC panel adjourns without vote on extending Johnson & Johnson COVID vaccine

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.